Clinical Trial Update: Phase 2 Trial of TD-6424 (Telavancin) Versus Standard Therapy for Complicated Gram Positive Skin and Skin Structure Infections (Gram Positive cSSSI) [Phase 2]

View source ↗

Summary

A Phase 2 trial comparing TD-6424 (telavancin) to standard therapy for complicated Gram-positive skin and skin structure infections has completed, with results …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Complicated Skin and Soft Tissue Infection
• Skin and Soft Tissue Infection

Drugs mentioned

• Telavancin (telavancin)

Snippet

Sponsor: Cumberland Pharmaceuticals | Conditions: Infections, Gram-positive Bacterial | Phase 2 | Status: COMPLETED | Results posted: 2010-01-11